Activated platelet surface

Activated platelet surface describes the array of membrane proteins, receptors, and lipid modifications that are exposed or upregulated when platelets become activated in response to physiological agonists such as thrombin, ADP, collagen, or shear stress[7][8]. Upon activation, platelets undergo dramatic shape changes, surface antigen expression (such as P-selectin and CD63), and upregulation/conformational change of integrins (notably GP IIb/IIIa/integrin αIIbβ3), facilitating aggregation and clot formation[2][5][8]. This surface forms the central therapeutic and diagnostic target in thrombosis and antiplatelet therapy, but is not a single molecular species; instead it represents a constellation of biochemical and morphological features—making it a "collective target" exploited for drug intervention and monitoring in cardiovascular and hematological conditions[8]. "Activated platelet surface" is not a standard single molecule or receptor name; it refers to the entire exposed surface of a platelet after activation, which includes many individual therapeutic and diagnostic targets. For structured database mapping, granular terms such as "Glycoprotein IIb/IIIa (integrin αIIbβ3)," "P-selectin," "CD63," "PAR-1," "P2Y12," etc., can be separately listed for specific pharmacological targeting.

Other names

Activated plateletsPlatelet activation markersPlatelet aggregates (activated)PAC-1 binding surface (refers to active GP IIb/IIIa on platelets)

Inhibition of receptor function (P2Y12, GPIIb/IIIa, PAR-1/4) Blocking platelet aggregation by ligand-receptor interaction Preventing activation-induced conformational changes Induction of receptor shedding by protease activation (e.g., by BTK inhibitors)